Skip to main navigation Skip to search Skip to main content

Forsythia velutina Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation

  • Yujin Kwon
  • , Yoon Jin Kang
  • , Jaeyoung Kwon
  • , Su Yeon Cho
  • , Jiyoon Kim
  • , Tam Thi Le
  • , Hoseong Hwang
  • , Barsha Deshar
  • , Myungjun Kim
  • , Ju Yeong Kim
  • , Jae Hung Jung
  • , Hyung Sik Kim
  • , Sang Hoon Jung
  • , Hak Cheol Kwon
  • , Won Kyu Kim

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Background: Atopic dermatitis (AD) is a complex condition characterized by impaired epithelial barriers and dysregulated immune cells. In this study, we demonstrated Forsythia velutina Nakai extract (FVE) simultaneously inhibits basophils, macrophages, keratinocytes, and T cells that are closely interrelated in AD development. Methods: We analyzed the effect of FVE on nitric oxide and reactive oxygen species (ROS) production in macrophages, basophil degranulation, T cell activation, and tight junctions in damaged keratinocytes. Expression of cell-type-specific inflammatory mediators was analyzed, and the underlying signaling pathways for anti-inflammatory effects of FVE were investigated. The anti-inflammatory effects of FVE were validated using a DNCB-induced mouse model of AD. Anti-inflammatory activity of compounds isolated from FVE was validated in each immune cell type. Results: FVE downregulated the expression of inflammatory mediators and ROS production in macrophages through TLR4 and NRF2 pathways modulation. It significantly reduced basophil degranulation and expression of type 2 (T2) and pro-inflammatory cytokines by perturbing FcεRI signaling. Forsythia velutina Nakai extract also robustly inhibited the expression of T2 cytokines in activated T cells. Furthermore, FVE upregulated the expression of tight junction molecules in damaged keratinocytes and downregulated leukocyte attractants, as well as IL-33, an inducer of T2 inflammation. In the AD mouse model, FVE showed superior improvement in inflammatory cell infiltration and skin structure integrity compared to dexamethasone. Dimatairesinol, a lignan dimer, was identified as the most potent anti-inflammatory FVE compound. Conclusion: Forsythia velutina Nakai extract and its constituent compounds demonstrate promising efficacy as a therapeutic option for prolonged AD treatment by independently inhibiting various cell types associated with AD and disrupting the deleterious link between them.

Original languageEnglish
Pages (from-to)1242-1257
Number of pages16
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume79
Issue number5
DOIs
StatePublished - May 2024

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Keywords

  • Forsythia velutina Nakai
  • atopic dermatitis
  • epithelial barrier
  • inflammation
  • natural product

Fingerprint

Dive into the research topics of 'Forsythia velutina Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation'. Together they form a unique fingerprint.

Cite this